Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
 Disease Progression Monitoring

Disease Progression Monitoring

EoETaly Guidelines Part-2

EoETaly Guidelines Part-2

 Smoldering Disease Overview

Smoldering Disease Overview

Smoldering Disease Detection

Smoldering Disease Detection

 Smoldering Disease Burden

Smoldering Disease Burden

 BTK Enzyme

BTK Enzyme

EoETaly Guidelines Part-1

EoETaly Guidelines Part-1

Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

An expert panel convened by EPOS2020 and EUFOREA proposed standardized definitions for disease control, remission, and progression in CRSwNP. This initiative aims to harmonize and optimize the standard of care for patients with CRSwNP.

EoE Pathophysiology

EoE Pathophysiology